A review on CXCR4/CXCL12 axis in oncology: No place to hide

Author:

Domanska Urszula M.,Kruizinga Roeliene C.,Nagengast Wouter B.,Timmer-Bosscha Hetty,Huls Gerwin,de Vries Elisabeth G.E.,Walenkamp Annemiek M.E.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Cited by 492 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Chemokine receptor CXCR4 interacts with nuclear receptor Nur77 and promote glioma invasion and progression;Brain Research;2024-01

2. Advances and Prospects in Integrated Nano-oncology;Nano Biomedicine and Engineering;2024-01

3. Understanding vitamin D from mouse knockout models;Feldman and Pike' s Vitamin D;2024

4. CXCR4 Theranostics: A Potential Game Changer in Solid Tumors and Hematological Malignancies;Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum;2024

5. CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology;European Journal of Nuclear Medicine and Molecular Imaging;2023-12-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3